Background: Twenty-four hour ambulatory electrocardiogram (AECG) monitoring is an established technique for integrated assessment of heart rhythm; however, comprehensive description of serial changes in cardiac electrophysiology over the first days of life in humans is lacking. The aim of this study was to determine the patterns of circadian heart rhythm based on AECG evaluation in newborns.

Methods: Twenty healthy newborns (14 boys and 6 girls) were serially examined with AECG at days 1, 2, and 4 after birth. Heart rate (HR), arrhythmias, QT dynamicity, microvolt T-wave alternans, and various indices of HR variability (HRV) including deceleration/acceleration capacity analysis were analyzed.

Results: There were no sex differences in HR. Supraventricular premature beats were noted in 35%, ventricular-in 15 % of newborns. Slope QT/RR was 0.35 (0.3-0.5); intercept QT/RR was 124 (93-148), QT/RR correlation coefficient (r) was 0.63 (0.53-0.85). Peak value of T-wave alternans was 32 +/- 8 (12-55) muV. Low level of HRV was typical for all parameters of time-domain analysis compared with normal limits for older children. The overall mean values of deceleration/acceleration capacity were 3.38 +/- 0.57 (2.16-4.13) and -3.58 +/- 0.67 (-2.13 to -4.38) milliseconds, respectively.

Conclusion: The healthy newborns exhibit peculiarities of 24-hour cardiac rhythm with isolated premature beats, pauses of sinus rhythm less 1000 milliseconds, steep slope of QT/RR by analysis of QT dynamicity. There are low HRV, and symmetrical AC/DC capacity was typically for autonomic regulation of HR, probably due to high sympathetic activity at this age.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jelectrocard.2009.11.001DOI Listing

Publication Analysis

Top Keywords

t-wave alternans
12
dynamicity microvolt
8
microvolt t-wave
8
heart rate
8
ambulatory electrocardiogram
8
heart rhythm
8
healthy newborns
8
deceleration/acceleration capacity
8
premature beats
8
slope qt/rr
8

Similar Publications

Objective: Treating iron deficiency (ID) with ferric carboxymaltose (FCM) in patients with heart failure with reduced ejection fraction (HFrEF) enhances morbidity, quality of life (QoL), and exercise capacity.

Methods: In the presented single-center, prospective follow-up study, symptomatic patients with HFrEF with ID and CIEDs scheduled for IV FCM were followed up for 12-months. Arrhythmic activity was evaluated from CIEDs and non-invasive markers from Holter recordings before and after FCM.

View Article and Find Full Text PDF

Background: Amiodarone and dronedarone are both class III antiarrhythmic medications used to treat arrhythmias. The objective of this study was to enhance the current understanding of adverse drug reaction (ADR) associated with amiodarone and dronedarone by employing data mining methods on the U.S.

View Article and Find Full Text PDF

A 58-year-old man presented with worsening dyspnea. Electrocardiogram showed variation in T-wave amplitude occurring every other beat. Transthoracic echocardiography revealed a severe aortic stenosis with beat-to-beat variation in stroke volume, suggestive of pulsus alternans.

View Article and Find Full Text PDF
Article Synopsis
  • - The K-REDEFINE study examined Heart Rate Turbulence (HRT) and T-wave alternans (TWA) as potential markers for predicting serious heart conditions in South Korean patients with acute myocardial infarction (MI) or heart failure (HF).
  • - The results showed that abnormal HRT was a strong predictor of adverse cardiac events, including cardiac death and hospitalizations due to heart failure, with a particularly high predictive value when combined with a reduced ejection fraction.
  • - In contrast, abnormal TWA was only associated with the overall risk of cardiac events and did not show as strong a predictive capability as HRT in this study.
View Article and Find Full Text PDF

Recurrent ventricular arrhythmias and heart failure induced by osimertinib- a case report.

Front Cardiovasc Med

August 2024

Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.

Article Synopsis
  • Osimertinib is a treatment for non-small cell lung cancer with EGFR mutations but poses risks of QT prolongation and heart failure, leading to rare but serious cardiac issues like ventricular fibrillation and Torsade de Pointes (TdP).
  • A 70-year-old woman experienced chest tightness and ventricular fibrillation after three months of osimertinib treatment, revealing severe QT prolongation and heart failure, requiring intensive management.
  • The case highlights the need for regular cardiac monitoring in patients taking osimertinib to prevent severe arrhythmias and manage potential heart complications effectively.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!